,9,10,11 BRAF/MEK inhibition has pleiotropic immunomodulatory effects like increased CD8+ T cell counts, increased major histocompatibility complex class I, and increased tumor antigen expression in melanoma and a concomitant reduction of the immunosuppressive tumor micromilieu.12 The gene discussed is CD8A; the disease is neoplasm.